Your browser doesn't support javascript.
loading
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos, V; Fariñas-Madrid, L; Gil-Martin, M; Barretina-Ginesta, P; Romeo, M; Villacampa, G; Pardo, B; Ahmed, H; Recalde, S; Piulats, J M; Gómez-Plaza, M C; Gil-Moreno, A; Sala, E; Martínez-Román, S; Ponce, J; Meléndez, C; Carballas, E; Dienstmann, R; Oaknin, A.
Afiliação
  • Rodriguez-Freixinos V; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Fariñas-Madrid L; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Gil-Martin M; Medical Oncology Department, Institut Català d'Oncologia (ICO), Barcelona, Spain.
  • Barretina-Ginesta P; Medical Oncology Department, Institut Català d'Oncologia (ICO)-Hospital Universitari Josep Trueta, Girona, Spain.
  • Romeo M; Medical Oncology Department, Institut Català d'Oncologia (ICO), Institut d'Investigació Germans Trias i Pujol, Badalona, Spain.
  • Villacampa G; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Pardo B; Medical Oncology Department, Institut Català d'Oncologia (ICO), Barcelona, Spain.
  • Ahmed H; Medical Oncology Department, Institut Català d'Oncologia (ICO)-Hospital Universitari Josep Trueta, Girona, Spain.
  • Recalde S; Medical Oncology Department, Institut Català d'Oncologia (ICO), Barcelona, Spain.
  • Piulats JM; Medical Oncology Department, Institut Català d'Oncologia (ICO), Barcelona, Spain.
  • Gómez-Plaza MC; Pathology Department, Institut Català d'Oncologia (ICO)-Hospital Germans Trias I Pujol, Badalona, Spain.
  • Gil-Moreno A; Gynaecology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Sala E; Gynaecology Department, Hospital Universitari Josep Trueta, Girona, Spain.
  • Martínez-Román S; Gynaecology Department, Hospital Germans Trias I Pujol, Badalona, Spain.
  • Ponce J; Gynaecology Department, University Hospital of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.
  • Meléndez C; Pathology Department, Hospital Universitari Josep Trueta, Girona, Spain.
  • Carballas E; Gynaecology Department, Hospital Germans Trias I Pujol, Badalona, Spain.
  • Dienstmann R; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Oaknin A; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: aoaknin@vhio.net.
Gynecol Oncol ; 152(2): 270-277, 2019 02.
Article em En | MEDLINE | ID: mdl-30551885
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Proteína BRCA1 / Proteína BRCA2 / Inibidores de Poli(ADP-Ribose) Polimerases / Mutação Tipo de estudo: Observational_studies Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Proteína BRCA1 / Proteína BRCA2 / Inibidores de Poli(ADP-Ribose) Polimerases / Mutação Tipo de estudo: Observational_studies Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha